AWM
DNA icon

Accel Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

Accel Wealth Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-359
Closed -$4.8K – 258
2024
Q2 		$4.8K Buy
+359
New +$10.7K ﹤0.01% 244

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Accel Wealth Management's DNA Position: Q3 2024 in Review

Accel Wealth Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 359 shares — an estimated $4.8K sold.

Accel Wealth Management first reported a position in DNA in Q2 2024 and held it in 1 quarter. The position peaked at $4.8K in Q2 2024. 158 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Accel Wealth Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Accel Wealth Management sold 359 Ginkgo Bioworks shares in Q3 2024, an estimated $4.8K.
  • Accel Wealth Management first reported a position in Ginkgo Bioworks in Q2 2024 and held it in 1 quarter.
  • Accel Wealth Management's Ginkgo Bioworks position peaked at $4.8K in Q2 2024.
  • 158 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Accel Wealth Management's 13F filing for Q3 2024, filed 15 Oct 2024.